Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the history of human disease treatment. Triterpenoid saponins have always been a hot topic in natural medicinal chemistry and pharmacology research due to their structural diversity and wide range of biological activities. Pulshinenoside B (CAS number: 135247-95-9) is derived from the traditional Chinese medicine, Pulshinenoside B（Pulsatilla chinensis A triterpenoid saponin with significant biological activity was isolated from the dried roots of Bunge Regel. As a commonly used traditional Chinese medicine, Bai Tou Weng has the effects of clearing heat and detoxifying, cooling blood, and stopping dysentery. It is commonly used in clinical practice to treat diseases such as heat toxicity and bloody dysentery, as well as swelling and pain in sores. Modern pharmacological research has shown that its active ingredients, saponins, are the main material basis for exerting pharmacological effects, among which Baitouweng saponin B has attracted much attention due to its outstanding activity in anti-tumor and other fields. In recent years, with the rapid development of molecular biology and cell biology technologies, research on the pharmacological activity and mechanism of action of Paeonia lactiflora saponin B has been continuously deepened, revealing its characteristics of exerting effects through multiple pathways such as regulating cell apoptosis, inhibiting tumor invasion and metastasis, and intervening in signal transduction pathways. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, molecular mechanism of action, pharmacological evaluation, and clinical application prospects of Paeonia lactiflora saponin B, in order to provide comprehensive scientific references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
Baitouweng saponin B belongs to the oleane type pentacyclic triterpenoid saponin. Its molecular formula is C ₅₄ H ₈₆ O ₂₄, and its molecular weight is 1075.2490. Its basic skeleton is oleanolic acid, with sugar chains connected at C-3 and C-28 positions, forming a double sugar chain saponin structure. Specifically, its sugar moiety is usually composed of monosaccharides such as glucose, arabinose, and xylose in a specific order and connection, and this complex glycosylation modification has a decisive impact on its water solubility and biological activity.
From the analysis of physical and chemical properties, the logarithmic (LogP) value of the lipid water partition coefficient of Paeonia lactiflora saponin B is 1.7031, indicating that it has a certain lipophilicity, but not high lipid solubility. Its topological polar surface area (TPSA) is as high as 353.9000 Å ², which is mainly attributed to the presence of a large number of hydroxyl groups and oxygen atoms on the sugar ring in the molecule, making the molecular polarity strong. The calculated water solubility value is 0.1925 mg/mL, belonging to the category of slightly soluble to poorly soluble, which is consistent with its high molecular weight and structural characteristics of polyhydroxy and polysaccharide groups. In practical applications, it may be necessary to improve its solubility through formulation techniques such as making cyclodextrin inclusion complexes, nanoparticles, etc. Preliminary pharmacological risk assessment shows that its ability to cross the blood-brain barrier is low, suggesting that its direct effect on central nervous system related diseases may be limited, but it may also reduce the risk of central nervous system side effects. In addition, according to the predicted data, it does not have significant potassium channel inhibitory activity (hERG inhibition: no) of human ether-a-go-go related genes (hERG inhibition: no), indicating a low potential risk of arrhythmia. The Ames test predicted a value of 0.0, indicating that it may not have direct genetic toxicity. These preliminary pharmacological parameters provide useful clues for further in-depth research.
Plant sources and extraction methods
The main source of Baitouweng saponin B is Baitouweng, a plant in the Ranunculaceae family and the Silver Lotus genus（Pulsatilla chinensis）Dry roots. This plant is widely distributed in Northeast, North, and East China, and is the authentic source of the traditional Chinese medicine "White Headed Weng". In addition, it belongs to other plants such as the Korean white headed Weng（P. cernua）Xing'an White Headed Weng（P. dahurica）It may also contain triterpenoid saponins with similar structures, but the specific composition and content may vary among species.
The extraction and isolation of saponins B from plant materials usually follow the conventional process of natural product chemistry. Firstly, crush the dried white haired Weng roots and extract them using a solvent of suitable polarity. Common methods include:
1. Solvent extraction method Methanol, ethanol, or ethanol water solutions of different concentrations are commonly used for reflux extraction or ultrasound assisted extraction. The ethanol extract is concentrated under reduced pressure to obtain a paste.
2. Purification and Separation The extract is usually suspended in water and extracted into segments using organic solvents such as petroleum ether, ethyl acetate, and n-butanol in sequence. Baitouweng saponin B is mainly enriched in the n-butanol extraction site. Subsequently, a variety of chromatographic techniques are comprehensively used for further separation and purification, such as macroporous adsorption resin column chromatography (commonly used AB-8, D101 and other models) for preliminary decolorization and enrichment, and then through silica gel column chromatography, reverse phase silica gel column chromatography (such as ODS), dextran gel column chromatography (such as Sephadex LH-20) and high performance liquid chromatography (HPLC) for fine separation, finally obtaining high-purity Pulsatilla saponin B monomer. Modern technologies such as high-speed countercurrent chromatography (HSCCC) are increasingly being used for the preparation and separation of such saponins due to their high efficiency and absence of solid adsorbent loss. The extraction and separation process requires tracking and detection using thin-layer chromatography (TLC) or HPLC to ensure the yield and purity of the target compound.
Pharmacological activity research
A large number of in vitro and in vivo pharmacological experiments have confirmed that Paeonia lactiflora saponin B has a wide range of biological activities, among which the most prominent and profound is its anti-tumor effect.
1. Antitumor activity
Studies have shown that Pulsatilla saponin B has significantly inhibited proliferation and induced apoptosis in a variety of human tumor cell lines, including but not limited to breast cancer, liver cancer, colon cancer, lung cancer, cervical cancer and leukemia cells.
* cytotoxicity This compound can inhibit the vitality of tumor cells in a dose-dependent and time-dependent manner.
* Inducing cell apoptosis This is one of the main mechanisms of its anti-tumor effect. Treatment with Baitouweng saponin B can lead to typical morphological changes of apoptosis in tumor cells, such as cell shrinkage, chromatin condensation, nuclear fragmentation, etc., accompanied by a significant increase in apoptosis rate.
* Inhibit cell migration and invasion In the cell models with high metastatic potential such as breast cancer and liver cancer, Pulsatilla saponin B can effectively inhibit the migration and invasion of cells, suggesting that it has the potential of anti-tumor metastasis.
* In vivo anti-tumor effect In a mouse model of transplanted tumors, intraperitoneal injection or gavage of Paeonia lactiflora saponin B can significantly inhibit tumor growth, reduce tumor volume and weight, and have little effect on mouse body weight within a certain dose range, showing a certain therapeutic window.
2. Other potential activities
In addition to anti-tumor effects, based on the traditional uses and modern research of Paeonia lactiflora, Paeonia lactiflora saponin B may also have anti-inflammatory, immune regulatory and other activities. However, there is relatively little systematic research in these areas, and further exploration is needed.
Mechanism of action and molecular targets
The anti-tumor effect of Paeonia lactiflora saponin B involves a complex regulatory network of multiple targets and pathways. According to existing research, its mechanism of action mainly revolves around inducing cell apoptosis, inhibiting cell survival signals, blocking the cell cycle, and inhibiting invasion and metastasis, involving multiple key molecular targets:
-
Regulating Bcl-2 family proteins and inducing mitochondrial pathway apoptosis B-cell lymphoma 2 (BCL2) and myeloid leukemia 1 (MCL1) are important anti apoptotic proteins. Research has shown that saponins B from Paeonia lactiflora can downregulate the expression of BCL2 and MCL1, while upregulating the expression of pro apoptotic proteins such as Bax, leading to a decrease in mitochondrial membrane potential, release of cytochrome C, and activation of the Caspase cascade reaction, ultimately triggering cell apoptosis. This is one of the core pathways through which it induces tumor cell death.
-
Inhibition of STAT3 signaling pathway Signal transduction and transcription activator 3 (STAT3) is a key oncogenic transcription factor, and sustained activation of STAT3 promotes cell proliferation, survival, and immune escape. Baitouweng saponin B can inhibit the phosphorylation (activation) of STAT3, block its nuclear translocation and the transcription of downstream target genes (such as Cyclin D1, Survivor, Bcl-2, etc.), thereby inhibiting tumor cell growth and promoting apoptosis.
-
Intervention in MAPK/ERK signaling pathway Mitogen activated protein kinase 1 (MAPK1, ERK2) is a key kinase in the MAPK/ERK pathway, involved in the transmission of cell proliferation and survival signals. Baitouweng saponin B can inhibit the phosphorylation of ERK, interfere with the abnormal activation of this pathway, and thus inhibit the proliferation of tumor cells.
-
Inhibition of matrix metalloproteinases and tumor invasion and metastasis Matrix metalloproteinase-2 (MMP2) is the main enzyme that degrades the extracellular matrix and plays a crucial role in tumor invasion and metastasis. Baitouweng saponin B can downregulate the expression and activity of MMP2, which is directly related to its inhibitory effect on tumor cell migration and invasion.
-
Affects DNA topoisomerase activity DNA topoisomerases I (TOP1) and II α (TOP2A) are key enzymes that regulate DNA topology and are targets of various chemotherapy drugs. Preliminary research suggests that saponins B from Paeonia lactiflora may interfere with the activity of these enzymes, affecting DNA replication and repair, but its specific mode of action still needs to be clarified.
-
Intervention of hypoxia inducible factors and estrogen related pathways In the tumor microenvironment, hypoxia inducible factor-1 alpha (HIF1A) regulates angiogenesis and metabolic adaptation. Estrogen receptor alpha (ESR1) and aromatase (CYP19A1) are important targets for the treatment of hormone dependent breast cancer. Studies have shown that saponins B from Paeonia lactiflora may affect the stability or activity of HIF1A and interfere with ESR1 signaling or CYP19A1 function in hormone sensitive tumors, but these mechanisms still require further experimental evidence to support.
In summary, Paeonia lactiflora saponins B form a multi-layered anti-tumor network by synergistically acting on multiple targets and pathways mentioned above, which may be the structural basis for its high efficacy and low toxicity potential.
Evaluation of drug properties and pharmacokinetics
Although Baitouweng saponin B exhibits strong anti-tumor activity in vitro, its successful development as a drug largely depends on its pharmacological properties, including pharmacokinetic properties and safety.
-
Absorption, distribution, metabolism, excretion (ADME)At present, there are insufficient reports on the pharmacokinetic studies of the Paeonia lactiflora saponin B system. Based on its high molecular weight (>1000 Da), high polarity (TPSA>300 Å ²), and poor water solubility, it can be inferred that its oral bioavailability may be low. Its absorption in the gastrointestinal tract may be limited by both poor permeability and enzymatic hydrolysis by gut microbiota (saponins are easily hydrolyzed into aglycones by gut microbiota). The distribution in the body may be mainly concentrated in organs with abundant blood flow, and it is difficult to cross the blood-brain barrier (predicted to be low). As a saponin compound, its metabolism may involve phase I and phase II reactions in the liver, as well as hydrolysis of gut microbiota. The prototype drug and its metabolites may be mainly excreted through bile and kidneys. It is urgent to use modern LC-MS/MS and other technologies to conduct systematic in vitro and in vivo ADME research, clarifying key parameters such as absolute bioavailability, major metabolites, tissue distribution characteristics, and elimination half-life.
-
Pharmaceutical Science Challenge As mentioned earlier, its water solubility and permeability are the main physical and chemical barriers for its drug formulation. Future formulation development may need to focus on nanocarrier systems (such as liposomes, polymer nanoparticles), self microemulsions, phospholipid complexes, or prodrug strategies to improve their solubility, stability, and biofilm permeability, thereby improving oral absorption or providing better formulation options for injection administration.
-
Preliminary Safety Assessment The existing predictive data suggests a low risk of hERG inhibition and genotoxicity, but this cannot replace comprehensive preclinical safety evaluation. Standardized acute toxicity, long-term toxicity, reproductive toxicity and other tests need to be conducted to clarify the safe dose range and treatment index. Saponin compounds generally have a certain hemolytic activity, which is also a safety indicator that needs to be focused on in the development of intravenous preparations of Paeonia lactiflora saponins B.
Clinical application prospects and prospects
As a natural product with multi-target anti-tumor activity, Baitouweng saponin B has broad clinical application prospects, but also faces challenges.
Potential application directions:
1. Development of anti-tumor drugs: As a single drug or in combination with existing chemotherapy drugs (such as topoisomerase inhibitors, tubulin inhibitors, etc.), it may be used to treat malignant tumors resistant to existing therapies or easy to metastasize, such as triple negative breast cancer, liver cancer, colorectal cancer, etc. Its multi-target characteristics may help overcome the problem of resistance that single target drugs are prone to.
2. Adjuvant therapy and chemotherapy sensitizers Its immunomodulatory and anti-inflammatory potential may enable it to play a role in improving the tumor microenvironment, enhancing the body's anti-tumor immune response, or as a sensitizer for chemotherapy/radiotherapy, improving the efficacy of traditional therapies.
3. Optimization based on traditional Chinese medicine compound formula Under the guidance of traditional Chinese medicine theory, clarifying the key pharmacological substance basis of Paeonia lactiflora saponins B as a medicinal herb of Paeonia lactiflora can help establish more precise quality control standards, optimize the modern formulation process of classic formulas containing Paeonia lactiflora (such as Paeonia lactiflora decoction), and promote the modernization of traditional Chinese medicine.
Challenges and future research directions:
1. In depth mechanism research It is necessary to use techniques such as gene knockout/knockdown, chromatin immunoprecipitation, proteomics, etc. to more accurately elucidate its direct interaction with the above targets and explore whether it affects emerging pathways such as tumor metabolism, autophagy, and ferroptosis.
2. Optimization of drug properties in the system Systematic preclinical pharmacokinetic and toxicological studies must be conducted. Meanwhile, strengthening pharmaceutical research and developing dosage forms suitable for clinical administration is a key step in promoting its transformation.
3. Structural modification and structure-activity relationship Using it as a lead compound, reasonable structural modifications (such as glycosylation and aglycone modifications) are carried out to improve its activity, selectivity, and drug properties, and to discover better candidate drugs.
4. Clinical translational research After completing sufficient preclinical research, gradually promote clinical studies that comply with Good Clinical Practice (GLP) and Good Clinical Practice (GCP) for drugs, and evaluate their safety, tolerability, and initial efficacy in humans.
Conclusion
Baitouweng saponin B is an active triterpenoid saponin isolated from the traditional Chinese medicine Baitouweng. It exhibits multi pathway and multi link anti-tumor effects by regulating multiple key targets such as MCL1, BCL2, STAT3, MMP2, MAPK1, etc., and has important development value. However, its poor solubility and potential pharmacokinetic defects are the main bottlenecks restricting its translation into clinical applications. Future research should adhere to a strategy that emphasizes both "deepening mechanisms" and "optimizing drug properties". On the one hand, multi omics techniques should be used to further reveal its complex biological activity network, and on the other hand, modern pharmacology and medicinal chemistry methods should be utilized to improve its physicochemical properties and in vivo fate. Through interdisciplinary collaborative innovation, it is expected to transform this ancient natural molecule into a new type of anti-tumor candidate drug with independent intellectual property rights, not only providing new options for tumor treatment, but also providing a model for the modern research of active ingredients in traditional Chinese medicine.
